Daily Briefing for November 7, 2026

Show Notes

U.S. measles cases pass 5,000, the most since 1991

The voices on this episode are generated, and so is the script, from the day's post at Physician in the Loop. Every fact in the post links to its source.

Read the post and its sources

Get the free email briefing

The United States has recorded 5,182 confirmed measles cases in 2026, the most since 1991, federal data released Friday showed, days before a regional review that could end the country's measles elimination status.

The count is more than double the 2,289 cases of 2025, and children and teenagers make up about 59% of them, according to Centers for Disease Control and Prevention figures reported by Bloomberg and Al Jazeera. The Pan American Health Organization said in March that it would review U.S. elimination status at its November meeting; a country loses the status after 12 months of uninterrupted spread of one viral lineage.

The Food and Drug Administration also opened an investigation of tumors in patients treated with the spinal muscular atrophy gene therapy Zolgensma, and HCA Healthcare said about 10,000 of its physicians will be documenting with ambient AI by year's end.

In this episode

• U.S. measles cases reach 5,182, the most since 1991, as elimination status goes up for review next week
• FDA investigates tumors after Zolgensma gene therapy, with viral DNA found inserted near a cancer gene in two patients
• HCA Healthcare puts ambient AI in the hands of 10,000 physicians by year's end and an AI nurse handoff tool in 100 hospitals
• An AI flag on positive ANA tests cut time to autoimmune diagnosis from 138 to 43 days in a Vanderbilt randomized trial
• Medicare cuts 340B drug payments to sales price minus 28% and pays office rates for hospital imaging off campus from 2027
• Ochsner plans primary care panels of 3,000 to 5,000 patients built around AI agents, pharmacists and ambient listening
• Starting overactive bladder patients on beta-3 agonists instead of anticholinergics did not lower dementia risk in an 830,393-patient cohort

What is Physician in the Loop?

How technological innovation is changing medicine for patients and the people who practice on the front lines.

Voice 1: This is Physician in the Loop, the daily briefing on AI in medicine. It's Saturday, November 7th, 2026.

Voice 1: 5,182. That’s how many measles cases the U.S. has confirmed this year, the most since 1991.

Voice 2: And that’s spread across how many states at this point?

Voice 1: 45 states. Nearly 5,000 of those cases are tied to ongoing outbreaks.

Voice 2: Who’s actually getting sick? Is this mostly kids?

Voice 1: Mostly. Children and teenagers make up about 59% of all cases, 18% in kids under five, 41% between five and nineteen.

Voice 2: That’s more than double where 2025 ended up, isn’t it?

Voice 1: It is. 2025 finished the year with 2,289 cases total, so this year already runs past double that.

Voice 2: What about deaths? I’ve seen different numbers floating around.

Voice 1: You should. The CDC counts four measles deaths nationally, but Pennsylvania alone counts six among its 1,487 cases, and New York and Wisconsin each reported a death this month. The CDC says it’s working with state epidemiologists on a standard definition of what counts as a measles death.

Voice 2: So the real toll could already be higher than the federal number says.

Voice 1: That’s the open question right now. Vaccination rates have slipped too: kindergarten MMR coverage dropped from about 95% in the 2019-2020 school year to about 92% this year.

Voice 2: And there’s a review next week tied to all of this?

Voice 1: The Pan American Health Organization said back in March it would review the country’s status at this November meeting. The test is whether one viral lineage has circulated continuously for 12 months, and Utah’s outbreak has been running since June of 2025.

Voice 2: The FDA opened its own investigation this week, into tumors in patients who got Zolgensma, the gene therapy for spinal muscular atrophy.

Voice 1: What actually ties the tumors to the therapy itself?

Voice 2: The FDA’s postmarketing reports include tumors in the central and peripheral nervous system, the spinal and paraspinal area, and the kidneys. In two cases, the therapy’s viral vector DNA was found inserted right next to a gene called GLI1, which is linked to cancer, and a third case involving that same gene is still under study. Novartis has said nine of about 6,000 recipients developed tumors.

Voice 1: Nine out of six thousand. Is the FDA telling physicians to stop using it?

Voice 2: No. The agency says the benefits still outweigh the risks. It’s also extending the warning to Itvisma, the version delivered into the spinal fluid, because it shares the same vector, even though no tumors have shown up with that one.

Voice 1: So what actually changes for a physician prescribing it tomorrow?

Voice 2: Nothing’s final. The FDA says it’s weighing whether the current labeling and follow-up studies go far enough.

Voice 1: A gene therapy question mark that’s going to sit over every one of those conversations for a while.

Voice 2: HCA Healthcare has its own AI story this week, rolling ambient documentation out to hospitalists and emergency physicians across more than 100 of its roughly 189 hospitals, plus about 3,000 outpatient clinicians, by the end of this year.

Voice 1: What’s that actually buying them, time-wise?

Voice 2: About five minutes back per note, or one to two hours a shift, according to HCA’s chief clinical officer, Dr. Michael Schlosser. He said outpatient physicians have used that time to add more patients to their schedules.

Voice 1: Any numbers on whether the notes hold up, or what it’s doing to claim denials?

Voice 2: Not yet. HCA says it’s tracking documentation completeness and denials, but hasn’t put out figures on either.

Voice 1: Is this just a trial run, or is it spreading company-wide?

Voice 2: HCA has invested in Commure directly and plans a companywide rollout by the end of 2027.

Voice 1: What about the nursing side of this rollout?

Voice 2: A separate AI handoff tool HCA built with Google is heading to about 100 hospitals within two months. In pilots, Schlosser said handoff-related safety events and near misses, quote, “basically have gone to zero.”

Voice 1: Pilots tend to look cleaner than scale does. Worth watching whether that number holds once it’s everywhere.

Voice 2: A Vanderbilt trial found something worth bringing up with a rheumatology colleague this week. Flagging high-risk positive ANA tests in the electronic record cut the time to an autoimmune diagnosis from 138 days down to 43.

Voice 1: That’s a big jump. What was the flag actually telling anyone to do?

Voice 2: It identified ANA-positive patients with high risk scores and routed them straight to an expedited rheumatology evaluation. It was a two-year randomized trial with 2,385 patients split roughly evenly between the intervention group and a control group.

Voice 1: Did more of them actually end up diagnosed, or just diagnosed sooner?

Voice 2: Mostly sooner. Among patients seen by rheumatology within six months, 23% of the intervention group got an autoimmune diagnosis versus 16% of the control group, but that gap wasn’t statistically significant on its own.

Voice 1: So the real win here is speed, not catching more disease.

Voice 2: That’s what the trial shows. The authors also point out there’s no existing evidence-based guidance for triaging a positive ANA result for referral in the first place.

Voice 1: Before we go, something to watch. The No Surprises Act’s IDR Gateway opens for web forms on November 13th.

Voice 2: What’s actually changing for a practice’s billing office?

Voice 1: Surprise-billing dispute forms move onto that Gateway, and the old web forms outside it shut down by January 15th, except for the resubmission form.

Voice 2: Two months isn’t much runway for a system nobody’s used yet.

Voice 1: Sources and corrections are at physicianintheloop.org, where you can sign up for the free email briefing. This briefing was read by AI voices.